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Two inducible enzymatic pathways (COX-2 and iNOS) that
produce mediators (prostaglandins and nitric oxide) known
to cause inflammation and tissue damage have recently
been discovered. These discoveries have led to novel
strategies to develop therapeutic agents to more effectively
treat arthritis. Both of these inducible enzymes have been
found in the osteoarthritic joint and the prostaglandins and
nitric oxide generated by these two enzymes appear to
contribute to the pain, swelling and cartilage destruction
characteristic of this progressive disease. Currently, aspirin
and the nonsteroidal anti-inflammatory drugs (NSAIDs) are
the most commonly used drugs to treat osteoarthritis (OA).
However, significant mechanism-based side effects, in par-
ticular GI ulceration, are commonly associated with this
treatment. Aspirin and the NSAIDs non-selectively inhibit
both the constitutive and inducible isoforms of cyclooxy-
genase, COX-1 and COX-2, respectively. Current evidence
strongly suggests that while the majority of side-effects
result from the inhibition of COX-1 activity, the anti-
inflammatory and analgesic actions of the NSAIDs are due
primarily to the inhibition of COX-2.1
To date, no NOS inhibitors are currently available for the
treatment of OA. Although iNOS expression and elevated
levels of nitrite (a stable oxidation product of nitric oxide)
have been found in the human OA joint, it remains to be
tested whether this type of therapeutic agent would be an
efficacious treatment for OA. Considerable evidence has
been generated in animal models which supports the
hypothesis that the inhibition of nitric oxide production
within the affected joint would reduce the pathological
changes associated with arthritis.2 Additionally, we have
found that nitric oxide stimulates the activity of the
cyclooxygenases, potentially leading to exaggerated levels
of prostaglandins in diseased tissues. This is of particular
importance relative to iNOS and COX-2, as we have found
that the expression of these two inducible proteins appears
to be regulated by the same factors and often occurs under
similar conditions in models of acute and chronic inflamma-
tion and in a number of human diseases including OA.367Indeed, we have observed in numerous animal models that
the selective inhibition of iNOS not only reduces nitric
oxide levels, but also significantly reduces the levels of
prostaglandins at the site of inflammation.3
Described in this brief review is a summary of our work
leading to the discovery of COX-2, the characterization of
the biological roles of COX-2 and COX-1, the identification
and characterization of selective COX-2 inhibitors, the
potential role of iNOS and nitric oxide in producing
pathological changes in arthritis and inflammation, and the
interactions between the COX-2 and iNOS pathways in
these processes.Correspondence: E-mail pamela.t.manning@monsanto.com;
Tel: (314)737-6248; Fax: (314)737-7388Discovery of inducible cyclooxygenase (COX-2)
The existence of an inducible form of cyclooxygenase
was proposed based upon the results from a number of
pharmacological studies which demonstrated that COX
activity was increased in vitro following treatment with
either cytokines or endotoxin and that COX activity was
markedly increased in vivo in inflamed tissue. In human
dermal fibroblasts, we observed that cytokine treatment
markedly elevated the COX activity and that this increased
activity was inhibited by glucocorticoid treatment.4 A
critical observation complementing the finding that gluco-
corticoid treatment blocked the induction of COX activity
was that glucocorticoids had no effect on basal COX
activity. Furthermore, inhibitors of either RNA or protein
synthesis also blocked this cytokine-induced COX activity.5
Similarly, we observed that endotoxin treatment of human
blood monocytes also caused a marked increase in COX
activity that was blocked by glucocorticoid treatment or
inhibitors of RNA and protein synthesis.6 These results
suggested that the increased prostaglandins produced
following cytokine treatment of either the human dermal
fibroblasts or blood monocytes was the result of de novo
cellular COX synthesis. In addition, we also observed an
increase in COX activity in murine peritoneal macrophages
isolated from mice which had been treated with endotoxin.7
As occurred in the in-vitro studies, the increased COX
activity was blocked by treatment of the mice with endo-
toxin and dexamethasone. Furthermore, adrenalectomy
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treated mice suggesting the regulation of this endotoxin-
inducible enzyme by endogenous glucocorticoids. Taken
together, these studies led us to hypothesize the presence
of a second form of COX and that its expression is induced
by cytokines or endotoxin and inhibited by glucocorticoids.
Finally, we speculated that at least part of the antiinflam-
matory activity of glucocorticoids is due to their ability to
block the synthesis of inducible COX activity in inflamed
tissue.
The constitutive form of cyclooxygenase, COX-1, was
cloned and sequenced from sheep seminal vesicles, a
tissue source known to be extremely rich in COX activity.8
Subsequently, the second form of cyclooxygenase, COX-2,
was cloned, sequenced and expressed from cDNA libraries
prepared from cells induced in vitro with mitogen, serum,
phorbol ester, or growth factors. COX-2 is encoded by a
gene distinct from COX-1 and is approximately 60% similar
within species to COX-1. Much of the divergence between
these two isozymes occurs at the amino and carboxy
termini. The central portion of the proteins are more highly
conserved suggesting similar structures for the substrate
and cofactor binding sites. The proteins are also conserved
across species with a greater than 85% similarity at the
amino acid level between both human and mouse COX-1
and human and mouse COX-2.8 Using specific cDNA
probes, the expression of COX-2 mRNA was subsequently
shown to be induced by cytokines and inhibited by gluco-
corticoids, confirming the presence and identity of the
9inducible isoform of COX, currently referred to as COX-2.Biological roles of COX-1 and COX-2
The biological roles for COX-1 and COX-2 are quite
distinct. COX-1 typically plays a constitutive or housekeep-
ing role while COX-2 plays a critical role in the inflammatory
disease process.1,9,10 Recent evidence also suggests that
COX-2 regulates the production of renin in the kidney.11
However, both isozymes catalyze the same initial reaction
resulting in the conversion of arachidonic acid to prosta-
glandins, PGG2 and PGH2, which are ultimately converted
to the more stable prostaglandins, prostacyclin and
thromboxane. COX-1 is normally found in most tissues and
is thought to produce prostaglandins that act locally, regu-
lating autocrine or paracrine functions. Indeed, COX-1 is
expressed throughout the gastrointestinal tract and in
platelets, the renal medulla and the vascular endothelium.
Among its many functions, COX-1 generates prostaglan-
dins which regulate vascular homeostasis and renal func-
tion and protect the gastrointestinal barrier. Inhibition of
COX-1 activity by NSAIDs is thought to cause their side-
effects including GI ulcers and decreased platelet function.
In addition, the renal side-effects attributed to NSAID
treatment is most likely due to inhibition of the renal
medullary COX-1. In contrast, COX-2 is not found in most
organs under normal conditions with the exception of the
rat brain (where COX-2 is expressed in neurons in certain
cortical locations) and the rat macula densa.11 The function
of COX-2 expression in these site has not yet been
determined. However, recent data suggests that the COX-2
present in the macula densa produces PGE2 that stimu-
lates the release of renin in low sodium states. The role of
COX-2 in inflammation is much more clear. COX-2 is
induced in inflamed tissues by a variety of inflammatory
stimuli and has been found in the joint tissue of both
rheumatoid12 and OA13 patients. COX-2 produces inflam-matory prostaglandins that cause edema and pain. COX-2
is also increased in the spinal cord in animal models of
inflammation and is thought to produce PGE2 as a mediator
of pain. Thus, the preponderance of data indicates that the
NSAIDs’ antiinflammatory activity results from the inhibition
of COX-2 activity, whereas the adverse effects associated
with this class of agents can largely be attributed to
inhibition the of COX-1 activity.Selective COX-2 inhibitors
Following the discovery of the inducible COX activity, its
association with inflammation and the identification of this
activity as COX-2, efforts were directed toward developing
a number of COX-2 selective inhibitors that would markedly
reduce inflammation without the accompanying GI ulcer-
ation and reduced platelet function associated with in-
hibition of COX-1 activity.14 Work at Searle and other
pharmaceutical companies have yielded both experimental
compounds (Dup 697, NS-398, flosulide and numerous
compounds synthesized by Searle and Merck) used for
concept testing in animal models and potential therapeutic
agents currently in late stage clinical trials, including the
most advanced of these agents, Searle’s celecoxib
(Celebrex). The COX-2 selective inhibitors have been
found to be effective at inhibiting acute and chronic inflam-
mation in numerous animal models, including carrageenan-
induced edema in the rat paw, carrageenan-induced
inflammation in the rat air pouch, and paw swelling and
inflammation in rat adjuvant-induced arthritis.14–17 In
addition, COX-2 inhibitors have been shown to be effective
analgesic agents in several animal models of pain.15,18 In
these models, it was clearly demonstrated that the COX-2
selective inhibitors were effective antiinflammatory and
analgesic agents with wide therapeutic margins with
respect to the GI ulceration and inhibition of platelet func-
tion.19 With regard to potential human therapeutics,
celecoxib has been found to be efficacious in human
clinical trials showing marked reduction in the signs and
symptoms of arthritis and exhibiting clear improvement in
the safety profile compared to the NSAIDs.20 Thus, a new
class of therapeutic agents, COX-2 specific inhibitors, is on
the verge of advancing into clinical practice and is expected
to provide a revolutionary breakthrough for the treatment of
the symptoms associated with arthritis due to its greatly
improved safety.Role of iNOS in arthritis and inflammation
A second cytokine-inducible enzyme, inducible nitric
oxide synthase (iNOS), has recently been identified which
generates high levels of nitric oxide from the amino acid,
arginine.2 The excessive production of nitric oxide appears
to elicit cellular cytotoxicity and tissue damage and is
thought to contribute to the pathology of several human
disease including OA.21 In addition, as with the cyclooxy-
genases, there are also constitutively expressed isoforms
of NOS which generate low amounts of nitric oxide neces-
sary for the regulation of numerous physiological pro-
cesses including blood pressure, platelet adhesiveness,
gastrointestinal motility, and neurotransmission, suggesting
the need for selective inhibition of the inducible enzyme in
the treatment of diseases in which iNOS contributes to the
pathophysiological changes. Interestingly, in many animal
models of acute and chronic inflammation and in a number
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similar manner and in similar sites as COX-2. In animal
models of inflammation, we have observed that selective
inhibitors of iNOS are effective at reducing carrageenan-
induced inflammation in the rat air pouch22 and inhibiting
the development of rat adjuvant-induced arthritis.23 In
addition, in carrageenan-induced inflammation of the rat
paw, selective iNOS inhibitors exhibited analgesic as well
as antiinflammatory activity.24 We have also demonstrated
that a selective iNOS inhibitor protects against the progres-
sion of osteoarthritis in a surgically-induced OA model in
the dog.25 These data suggest that selective iNOS inhibi-
tors may not only be effective agents for the treatment of
the signs and symptoms of osteoarthritis (due to their
antiinflammatory and analgesic actions), but also may
possess disease modifying activity.Interactions between the COX-2 and iNOS
pathways
COX-2 and iNOS are often expressed together in
inflamed tissues and are induced by many of the same
cytokines. Indeed, these inducible enzymes are found in
both rheumatoid and osteoarthritic tissues, and it is likely
that the edema, pain, and tissue destruction associated
with these conditions is the result of both of these pathways
playing critical roles in the disease process (Fig. 1). Efforts
have been directed toward understanding the role of iNOS
in the regulation of COX-2 activity. Specifically, we have
found that nitric oxide produced by iNOS increases the
enzymatic activity of COX-2.26 The mechanism of this
activation of COX-2 by nitric oxide is not completely under-
stood, but it appears to be mediated through peroxynitrite
activation of the peroxidase activity of COX-2.27 It is clear,
however, that nitric oxide, either directly or indirectly
through peroxynitrite, causes a marked increase in COX-2
activity in numerous cell types. We have observed in bothin vitro and in vivo paradigms, that selective inhibitors of
iNOS reduce the production of nitric oxide and as a result
of this reduced nitric oxide, also decrease the production of
prostaglandins by COX-2.28 This inhibition of COX-2
activity following iNOS inhibition can be reversed in vitro by
the addition of nitric oxide donors. In addition, in vivo in the
experimental canine OA model, the selective inhibition of
iNOS significantly reduced the level of PGE2 in the synovial
fluid25 and the expression of COX-2 in the tissue (sub-
mitted for publication). The implications of the finding that
iNOS regulates COX-2 activity is that many of the anti-
inflammatory actions of COX-2 inhibitors may also be
observed for iNOS inhibitors as a result of this action on the
COX-2 enzyme.Conclusion
The discovery and characterization of the functions of
the inducible COX and NOS isozymes has provided the
impetus for novel therapeutic approaches directed toward
developing potentially two new classes of drugs. Antiinflam-
matory agents with efficacy equivalent or better than the
NSAIDs and having markedly improved safety profiles are
rapidly advancing in clinical trials as specific COX-2 inhibi-
tors and should be available for the treatment of the signs
and symptoms of RA and OA before the end of this century.
This breakthrough will have profound implications for the
ability of the physician to provide relief to the arthritic
patient in a context of increased safety. Even though iNOS
inhibitors lag behind the specific COX-2 inhibitors in their
clinical development, the potential for these agents is that
in addition to reducing the signs and symptoms of OA, they
may also possess disease modifying activity and thereby
provide ‘chondroprotection’.Fig. 1. Interaction between the COX-2 and iNOS pathways.
Inflammatory stimuli including endotoxin and numerous cytokines
induce the expression of both COX-2 and iNOS at sites of
inflammation or tissue injury. The prostaglandins and nitric oxide
generated by these enzymes contribute to the pathology of arthritis
including pain, swelling and joint destruction. As indicated by the
dashed arrow, nitric oxide can increase the activity of COX-2 to
produce even greater amounts of inflammatory prostaglandins.References
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